Navigation Links
Axikin Pharmaceuticals Spins out of Actimis
Date:1/22/2009

SAN DIEGO, Jan. 22 /PRNewswire/ -- Axikin Pharmaceuticals, Inc., a startup company dedicated to developing and commercializing small molecule therapeutics for respiratory and inflammatory diseases, today announced a $3 million private placement of its Series A stock. The financing was led by Sanderling Ventures of San Mateo, California. Additional investors include Mitsui & Co. Venture Partners of New York.

Axikin Pharmaceuticals, Inc., was formed as a spin-out from Actimis Pharmaceuticals, Inc., (www.actimis.com) following the acquisition of Actimis' lead program by Boehringer Ingelheim in a structured buyout in June 2008. Axikin's pipeline includes an advanced pre-clinical program with multiple highly optimized small-molecule lead candidates, as well as two additional novel target research programs. These programs are expected to have broad applications across respiratory and allergic diseases including asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD) with, potentially, broader applications in inflammation, autoimmunity, oncology and cardiovascular disease.

"The establishment of Axikin Pharmaceuticals, Inc., and the additional funding we have received to progress these assets, allows us to hit the ground running and provide significant continuity in the quest to bring our lead candidates to the clinic," said Kevin B. Bacon, Ph.D., founder, President and Chief Scientific Officer of Axikin, and original founder of Actimis. "Building on our excellent relationship with our prior investor partners, and retaining the same team of highly-dedicated scientists greatly facilitates our goal of filing an investigational new drug application (IND) for our lead program in the very near future."

"The investors are delighted to be backing the same proven team again in this new spin-out Company," said Peter C. M. McWilliams, Ph.D., Chairm
'/>"/>

SOURCE Axikin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Mechanicsburg, Pa (PRWEB) May 20, 2013 ... controller with ramp/soak capabilities. The 5R6-900 benchtop controller ... enclosure, the device can be plugged into the wall ... own power supply. This distinctive detail makes the device ... , The laboratory temperature controller can also be ...
(Date:5/20/2013)...  (PSHR) Pacific Shore Holdings, Inc. a consumer ... broad range of product categories lines, today reports ... BlueWater Advisory Group, to provide strategic counsel and ... to direct the company,s outreach and investor awareness ... Matthew Mills , Pacific Shore Holdings, president ...
(Date:5/20/2013)... 20, 2013 With bed bugs' presence come ... although bed bugs need to be eliminated, one must make ... a person's health. And so to help bed bug sufferers ... get rid of bed bugs without using harmful pesticides. ... spray it called Bed Bug Bully. , According to My ...
(Date:5/20/2013)... --  Flexion Therapeutics , Inc. today announced the addition ... its management team as chief financial officer. Mr. Driscoll ... with biotechnology and medical device companies. Prior ... for Novavax (NASDAQ: NVAX ) where he ... through a combination of investment funding and commercial and ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2
... RANCHO CORDOVA, Calif., Feb. 22 ThermoGenesis,Corp.(Nasdaq: KOOL ... recall of,certain lots of its AXP(TM) AutoXpress Platform(TM) (AXP) ... in a document review process that,some lots of the ... testing, which is a manufacturing release criterion., The ...
... Biopure Corporation,(Nasdaq: BPUR ) today announced its ... 2008. For the quarter, the company reported a net,loss ... with a net loss,of $6.9 million, or $0.53 per ... common shares outstanding on January 31, 2008 and 2007 ...
... grow over 5% annually over the next five ... years, according to Millennium Research Group, WALTHAM, Mass., Feb. ... 2008 report, the US market for,fixed C-arm systems, comprising units ... $1.4 billion in 2007 and will,rise to over $1.8 billion ...
Cached Biology Technology:ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets 2Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7Fixed C-Arms Revolutionize Operating Room Environments 2
(Date:5/21/2013)... -- Royal Philips Electronics (NYSE: PHG, AEX: PHIA) today ... with Philips, industry leading Live 3D TEE, now offers ... available Live 3D TEE and ICE will be shown ... official meeting for the European Association of Percutaneous Cardiovascular ... in 2012, Philips CX50 xMATRIX has been the only ...
(Date:5/21/2013)... way genes function without changing the underlying DNA ... of pregnant women during any trimester, potentially providing ... weeks after giving birth, and an opportunity to ... of the small study involving 52 pregnant women ... Psychiatry . , "Postpartum depression can be harmful ...
(Date:5/20/2013)... resistant to the antibiotic colistin are also commonly ... body, according to a study in mBio ... Society for Microbiology. Cross-resistance to colistin and host ... body against bacterial attack, could mean that patients ... with a crippled immune response. Colistin is a ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... 2012  Medbox, Inc. (Pinksheets: MDBX) ( www.medboxinc.com ) ... new, highly secure, automated kiosk for the storage ... which uses biometric fingerprint recognition, safely stores medicines ... The system also provides a permanent record of ...
... German . Microscopes provide valuable insights in ... the latter remain in their natural environment. However, this ... Karlsruhe Institute of Technology (KIT), the Max Planck Institute ... of Health (NIH) have now developed a new method ...
... 16, 2012 Cardium Therapeutics (NYSE Amex: CXM) today ... of Gene & Cell Therapy (ASGCT) 15th Annual Meeting ... Center in Philadelphia, PA. The ... important role in adenovector gene transfection (delivery) in mammalian ...
Cached Biology News:Medbox Developing a Patent Pending Wall-Mounted Biometric Kiosk for Storage of Sensitive Medicine Samples and Supplies for Doctor's Offices. 2Nature: Microscope looks into cells of living fish 2Delivery of gene-therapy for heart disease boosted 100-fold; now in 100-patient trial 2
...
... Mynox is the first ... by killing them, and not ... is the only anti-mycoplasma agent ... clean virus stocks directly. The ...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
... (EMSA) is a powerful tool for evaluating ... shift or gel retardation, the assay is ... to electrophoresis, free DNA will migrate differently ... Chemiluminescent EMSA Kit is a nonradioactive system ...
Biology Products: